Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutated Lung Adenocarcinoma”

74 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 74 results

Large-scale testing (Phase 3)Study completedNCT01719536
What this trial is testing

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients

Who this might be right for
NSCLC
Betta Pharmaceuticals Co., Ltd. 296
Not applicableUnknownNCT05136014
What this trial is testing

Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model

Who this might be right for
Lung CancerLung AdenocarcinomaEGFR Activating Mutation+2 more
Central Hospital, Nancy, France 200
Not applicableStudy completedNCT03059641
What this trial is testing

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

Who this might be right for
Lung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more
Geneplus-Beijing Co. Ltd. 300
Testing effectiveness (Phase 2)Study completedNCT04770688
What this trial is testing

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR MutationLocally Advanced Solid TumorMetastatic Cancer+1 more
Shanghai Chest Hospital 25
Not applicableStudy completedNCT04370860
What this trial is testing

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Who this might be right for
EGFR Exon 19 MutationTumor Progression
National Taiwan University Hospital 1,000
Testing effectiveness (Phase 2)UnknownNCT02036359
What this trial is testing

Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)
National Taiwan University Hospital 76
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07624487
What this trial is testing

Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

Who this might be right for
Lung Adenocarcinoma Metastatic
Taipei Medical University Hospital 50
Not applicableStudy completedNCT01167972
What this trial is testing

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 2,000
Not applicableUnknownNCT06207292
What this trial is testing

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer

Who this might be right for
NSCLCNSCLC Stage IVOligometastatic Disease+9 more
Radiotherapy Oncology Centre "Santa Maria" Hospital 100
Not applicableNot Yet RecruitingNCT07287904
What this trial is testing

Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

Who this might be right for
Lung Cancer (NSCLC)EGFR Activating MutationAdenocarcinoma Lung+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 1,000
Testing effectiveness (Phase 2)Study completedNCT02264210
What this trial is testing

Icotinib for Completed Resected IB NSCLC With EGFR Mutation

Who this might be right for
Lung NeoplasmsSquamous Cell Lung CancerAdenocarcinoma of the Lung+4 more
Sun Yat-sen University 128
Testing effectiveness (Phase 2)Ended earlyNCT02485652
What this trial is testing

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 162
Testing effectiveness (Phase 2)UnknownNCT02737774
What this trial is testing

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Who this might be right for
Lung Adenocarcinoma
Henan Cancer Hospital 60
Testing effectiveness (Phase 2)UnknownNCT03486496
What this trial is testing

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Who this might be right for
Lung AdenocarcinomaEGFR Mutation
Fujian Cancer Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT05528458
What this trial is testing

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Who this might be right for
Lung Adenocarcinoma
Samsung Medical Center 59
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)UnknownNCT05079022
What this trial is testing

CtDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Who this might be right for
Adenocarcinoma of Lung
Peking University People's Hospital 50
Testing effectiveness (Phase 2)Ended earlyNCT01819428
What this trial is testing

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

Who this might be right for
Adenocarcinoma of Lung Stage IIIBAdenocarcinoma of Lung Stage IV
National OncoVenture 22
Testing effectiveness (Phase 2)Study completedNCT01610336
What this trial is testing

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 161
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06951399
What this trial is testing

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC Stage IV Without EGFR/ALK MutationNSCLC Adenocarcinoma
Rabin Medical Center 30
Load More Results